流行的糖尿病药物可能会增加病人的骨折危险

Popular diabetes drugs "increase risk for fractures in patients"
流行的糖尿病药物会增加病人的骨折危险广州中医药大学第一附属医院脊柱专科梁德
摘自 丁香园 论坛 ，翻译者：eree

A new study has revealed that postmenopausal women with diabetes taking thiazolidinediones (TZDS), including rosiglitazone and pioglitazone, may be at increased risk for fractures.
一项新的研究显示患有糖尿病的绝经妇女在服用噻唑烷二酮类药物，包括匹格列酮与罗格列酮时，会增加骨折的危险。
Men with diabetes taking both loop diuretics and TZDs may also be at increased risk of fractures, according to the research.
依照这一研究，患有糖尿病的男性在同时服用髓袢利尿药和噻唑烷二酮类药物时也会增加骨折的危险。
"Our study shows that increased fracture risk is associated with higher TZD dose, but no difference between rosiglitazone and pioglitazone is apparent suggesting a class effect of TZDs on fracture risk," said William Herman, of the University of Michigan in Ann Arbor and senior author of the study.
“我们的研究展现了骨折增加的危险与高剂量的TZD有关，匹格列酮与罗格列酮没有什么不同，显然为一类TZD药物，影响骨折危险。”这一研究的资深人士，美国安阿伯市密西根大学的威廉赫尔曼说道。
"Physicians should be aware of this risk and weigh the benefits and risks of therapy when they initially prescribe or renew prescriptions for TZDs," he added.
“内科医生对于TZDS在最初开处方或重新开处方时，应该意识到这一危害并权衡一下治疗的利弊。”他补充道。
Using data from Translating Research into Action for Diabetes (TRIAD), a multi-center prospective observational study of diabetes care in managed care, researchers conducted a matched case-control study to assess the odds of TZD exposure in patients with type 2 diabetes with and without fractures. From the study, researchers identified 786 cases of fractures and 2,657 matched controls (diabetes patients without fractures).
应用的数据来自于糖尿病的调查活动研究（TRIAD），在管理医疗中，一个多中心前瞻性的观察糖尿病护理研究，研究者管理一个相应的病例对照研究，去评估2型糖尿病患者服用不同剂量的TZD，是否发生骨折。来自于这项研究，调查者鉴别786起骨折事件和2657起相应对照组（没有骨折的糖尿病患者）。

Women aged 50 years and older with fractures, when compared to their matched controls, were significantly more likely to have filled prescriptions for TZDs.
当对照与她们相对应的对照组，50岁和更老的骨折妇女会更显著，是应用了大剂量的处方药TZDS。
Men with fractures were more likely to have filled prescriptions for TZDs and loop diuretics when compared to their matched controls. This result is particularly interesting because in men, loop diuretics or TZDs alone did not confer significant risks.
骨折的男性更多的是服用了处方药髓袢利尿药和药物，当对照与他们相应对照组。这一结果特别令人感兴趣，因为男性，单独使用髓袢利尿药或噻唑烷二酮类药物，都不能形成显著的危害。
"Future studies, particularly long-term, prospective randomized clinical trials will be needed to conclusively demonstrate small to moderate harm," said Herman.
“进一步研究，特别是长期的，前瞻性的随机临床试验，应该需要去最终证明小剂量去调节危害，”赫尔曼说道。
The new study has been accepted for publication in The Endocrine Society"s Journal of Clinical Endocrinology and Metabolism (JCEM). (ANI)
这一新的研究被接收出版在内分泌学会的内分泌和新陈代谢临床杂志。